+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients



A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients



Anaesthesia 63(1): 52-64



The utility of peri-operative statin therapy is currently considered to be inconclusive. To provide a platform for more meaningful peri-operative statin literature in the future, this is the first of two review articles evaluating peri-operative statin therapy. This review examines the predictors of cardiovascular outcome and therapeutic targets which are established in medical (non-surgical) patients. In patients with stable coronary artery disease at least 4-6 weeks of standard statin therapy are required to realise most of the beneficial cellular and metabolic effects of statin therapy. Low-density lipoprotein-cholesterol reduction is associated with improved survival in these patients. In comparison, patients who sustain an acute coronary event require high-dose statin therapy probably initiated within 24 h with a therapeutic target of C-reactive protein reduction. Withdrawal of statin therapy results in a rapid return to endothelial dysfunction and amplification of the inflammatory process, which may increase cardiovascular risk.

(PDF emailed within 0-6 h: $19.90)

Accession: 051206665

Download citation: RISBibTeXText

PMID: 18086071

DOI: 10.1111/j.1365-2044.2007.05264.x


Related references

A peri-operative statin update for non-cardiac surgery. Part II: Statin therapy for vascular surgery and peri-operative statin trial design. Anaesthesia 63(2): 162-171, 2008

Hemodynamic effects of peri-operative statin therapy in on-pump cardiac surgery patients. Journal of Cardiothoracic Surgery 7(1): 39, 2012

Hemodynamic effects of peri-operative statin therapy in on-pump cardiac surgery patients. Journal of Cardiothoracic Surgery 7: 39, 2013

Peri-operative fluid strategy and post-operative acute kidney injury in cardiac surgery patients: any role for pre-operative statin therapy?. Critical Care 19: 453, 2016

A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Journal of Cardiology 60(1): 12-17, 2013

Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis 224(2): 454-456, 2013

Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. Anaesthesia 60(11): 1106-1114, 2005

Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis 23(7): 848-856, 2017

Tu-W27:4 Comparative lipid effects of combination therapy with a statin and extended-release niacin versus statin plus ezetimibe versus a statin alone. Atherosclerosis Supplements 7(3): 174-175, 2006

A response to 'statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease'. Anaesthesia 61(3): 307; Author Reply 308-307; Author Reply 308, 2006

RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids in Health and Disease 12: 142, 2014

Insulin resistance due to statin therapy: a potential contributor to the negation of statin-induced beneficial effects on cardiac remodelling in heart failure?. International Journal of Cardiology 146(3): 417, 2011

Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coronary Artery Disease 22(5): 352-358, 2011

Still without impact on adverse post-operative outcomes: pre-operative statin therapy in patients undergoing cardiac surgery. European Heart Journal 29(19): 2444; Author Reply 2444-5, 2008

Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clinical Cardiology 37(11): 653-659, 2015